You are here: Home » International » News » Others
Business Standard

WTO members to intensify talks on patent waiver for Covid drugs, vaccines

India, in last informal meeting of TRIPS Council, had urged all members to begin text-based negotiations on the waiver proposal

Topics
World Trade organisation | Coronavirus | Coronavirus Vaccine

Agencies  |  Geneva 

Photo: Bloomberg
TRIPS Council has reportedly agreed with consensus to go ahead with text-based negotiations on waiver proposal (Photo: Bloomberg)

member states agreed on Wednesday to intensify talks toward improving access to COVID-19 products, as developing nations push for a proposal to ease patent and other legal protections on vaccines - and some wealthier countries remain stiffly opposed.

TRIPS Council, a WTO panel focusing on intellectual property, which includes patents on technological know-how like vaccines and the processes to manufacture them, wrapped up a two-day meeting on Wednesday with an agreement to start a text-based process to pull together proposals about improving the fight against COVID-19 through the Geneva-based trade body's intricate system of rules.

TRIPS is Trade-Related Aspects of Intellectual Property Rights Agreement. India, in last informal meeting of TRIPS Council, had urged all members to begin text-based negotiations on the waiver proposal. India and more than 60 other nations had sought a TRIPS waiver to increase vaccine manufacturing.

The goal is to help jump-start lagging efforts to get vaccines to developing-world countries that badly need them, according to a Geneva-based trade official, who spoke on condition of anonymity because he was not authorised to speak publicly on the matter.

New, informal talks will start next week among members of the panel, with an eye toward pulling together a report for a meeting of WTO ambassadors on July 21-22.

South Africa and India floated the proposal for a temporary easing of patent protections for COVID-19 vaccines, therapies and tests - known as an IP waiver -- last fall. While many developed countries with strong pharmaceutical industries hesitated about or were outright opposed that idea, the debate received a jolt last month when the Biden administration announced support for an IP waiver for vaccines alone.

In the two days of talks, South Africa and India laid out a revision of their proposal - now backed by over 60 countries - that insisted on the three-year temporary nature of the waiver for COVID-19 products, the trade official said.

But some countries - notably the European Union's 27 member states, as well as Britain, Switzerland and Korea - continue to oppose a waiver, the official said, relaying deliberations in the closed-door talks Tuesday and Wednesday.

Countries like Australia, Brazil, Canada, China and the United States haven't rallied fully behind the South African and Indian proposal, and view it as just one part of what they believe should be a more comprehensive approach in getting COVID-19 products to the developing world, the official said.

Even optimistic supporters acknowledge an IP waiver could take months to finalise because of the resistance and WTO rules that require consensus on such decisions -- meaning a single country among the 164 members could scuttle any proposal. Even if one were adopted, ratification would also take time.

Advocacy groups, emboldened by the support the US announced last month, have increasingly pushed the plan and insisted it would not be as difficult to carry out as its opponents say.

Pharmaceutical companies insist that an IP waiver could dampen the incentive for researchers and entrepreneurs to innovate, and say vaccine-sharing by rich countries would be a much faster way to get shots to health workers and at-risk populations in the developing world.

The World Health Organisation has repeatedly inveighed against unequal access to vaccines, noting that rich countries scooped up supplies well in excess of the need of their own populations while developing countries have obtained only a small fraction of the doses so far distributed and used worldwide.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, June 09 2021. 18:59 IST
RECOMMENDED FOR YOU